LENZ Therapeutics, Inc.

NasdaqGS:LENZ Stock Report

Market Cap: US$897.4m

LENZ Therapeutics Management

Management criteria checks 3/4

LENZ Therapeutics' CEO is Eef Schimmelpennink, appointed in Mar 2021, has a tenure of 3.75 years. total yearly compensation is $2.52M, comprised of 21.3% salary and 78.7% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth $1.47M. The average tenure of the management team and the board of directors is 2.2 years and 3.5 years respectively.

Key information

Eef Schimmelpennink

Chief executive officer

US$2.5m

Total compensation

CEO salary percentage21.3%
CEO tenure3.8yrs
CEO ownership0.2%
Management average tenure2.2yrs
Board average tenure3.5yrs

Recent management updates

Recent updates

LENZ Therapeutics: Time For A Pause

Nov 27

LENZ Therapeutics: Upcoming PDUFA, Strong Data, Some Risks

Aug 30

CEO Compensation Analysis

How has Eef Schimmelpennink's remuneration changed compared to LENZ Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$61m

Jun 30 2024n/an/a

-US$69m

Mar 31 2024n/an/a

-US$74m

Dec 31 2023US$3mUS$537k

-US$70m

Sep 30 2023n/an/a

-US$56m

Dec 31 2022US$1mUS$508k

-US$11m

Compensation vs Market: Eef's total compensation ($USD2.52M) is about average for companies of similar size in the US market ($USD3.24M).

Compensation vs Earnings: Eef's compensation has increased whilst the company is unprofitable.

CEO

Eef Schimmelpennink (52 yo)

3.8yrs

Tenure

US$2,517,407

Compensation

Mr. Evert B. Schimmelpennink, also known as Eef, serves as Director of Pipeline Therapeutics, Inc. since February 2022. He serves as an Independent Director at Contineum Therapeutics, Inc. since January 20...

Leadership Team

NamePositionTenureCompensationOwnership
Evert Schimmelpennink
President3.8yrsUS$2.52m0.16%
$ 1.5m
Shawn Olsson
Chief Commercial Officer3.7yrsUS$795.02k0.012%
$ 108.8k
Marc Odrich
Chief Medical Officerless than a yearUS$920.16k0.36%
$ 3.2m
James McCollum
Co-Founder & Directorno datano data2.26%
$ 20.3m
Daniel Chevallard
Chief Financial Officerless than a yearno data0.012%
$ 104.0k
Domenick Porfidia
Vice President of Salesno datano datano data
David Murphy
Vice President of Marketingno datano datano data
Breianna Bowen
Vice President of Human Resourcesno datano datano data
Marvin Garrett
Senior Vice President of Regulatory & Qualityno datano datano data

2.2yrs

Average Tenure

58.5yo

Average Age

Experienced Management: LENZ's management team is considered experienced (2.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Evert Schimmelpennink
President3.8yrsUS$2.52m0.16%
$ 1.5m
James McCollum
Co-Founder & Director11.4yrsno data2.26%
$ 20.3m
Shelley Thunen
Independent Directorless than a yearno data0%
$ 0
Terry Kim
Member of Medical Advisory Boardno datano datano data
Robert Osher
Member of Medical Advisory Boardno datano datano data
Colman Kraff
Member of Medical Advisory Boardno datano datano data
Steven Dell
Member of Medical Advisory Boardno datano datano data
John Doane
Member of Medical Advisory Boardno datano datano data
Jeffrey George
Independent Chairmanless than a yearno data0%
$ 0
Frederic Guerard
Independent Director3.3yrsno data0%
$ 0
Deepinder Dhaliwal
Member of Medical Advisory Boardno datano datano data
Zachary Scheiner
Independent Director4.2yrsno data0%
$ 0

3.5yrs

Average Tenure

52yo

Average Age

Experienced Board: LENZ's board of directors are considered experienced (3.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 06:08
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

LENZ Therapeutics, Inc. is covered by 8 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
Yigal NochomovitzCitigroup Inc
Matthew CaufieldH.C. Wainwright & Co.